- Home
- GLTO vs BGI Comparison
GLTO vs BGI Comparison
Compare GLTO & BGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- BGI
- Stock Information
- Founded
- GLTO 2011
- BGI 1879
- Country
- GLTO Denmark
- BGI Canada
- Employees
- GLTO N/A
- BGI N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- BGI
- Sector
- GLTO Health Care
- BGI
- Exchange
- GLTO Nasdaq
- BGI Nasdaq
- Market Cap
- GLTO 23.7M
- BGI 22.7M
- IPO Year
- GLTO 2020
- BGI 2005
- Fundamental
- Price
- GLTO $5.72
- BGI $1.12
- Analyst Decision
- GLTO
- BGI
- Analyst Count
- GLTO 0
- BGI 0
- Target Price
- GLTO N/A
- BGI N/A
- AVG Volume (30 Days)
- GLTO 767.1K
- BGI 55.2K
- Earning Date
- GLTO 11-04-2025
- BGI 11-26-2025
- Dividend Yield
- GLTO N/A
- BGI N/A
- EPS Growth
- GLTO N/A
- BGI N/A
- EPS
- GLTO N/A
- BGI N/A
- Revenue
- GLTO N/A
- BGI $124,446,731.00
- Revenue This Year
- GLTO N/A
- BGI N/A
- Revenue Next Year
- GLTO N/A
- BGI N/A
- P/E Ratio
- GLTO N/A
- BGI N/A
- Revenue Growth
- GLTO N/A
- BGI N/A
- 52 Week Low
- GLTO $2.01
- BGI $0.56
- 52 Week High
- GLTO $31.70
- BGI $2.20
- Technical
- Relative Strength Index (RSI)
- GLTO 42.06
- BGI 47.59
- Support Level
- GLTO $7.02
- BGI $1.13
- Resistance Level
- GLTO $7.64
- BGI $1.14
- Average True Range (ATR)
- GLTO 0.58
- BGI 0.05
- MACD
- GLTO -0.55
- BGI -0.01
- Stochastic Oscillator
- GLTO 0.25
- BGI 3.85
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.